Objective Coronavirus disease 2019 (COVID-19) is a world-wide pandemic caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, treatment of severe …

… cases with an initial STT value of 0 to 2 mm/min, STT values increased to 5 mm/min in 59%
of eyes after topical treatment. Even in cases … tissue has been noted in severe cases of KCS [ …

… According to theory of disease tolerance the most severe cases … HCQ doses plus
immunomodulatory agents such as tocilizumab, … a possible benefit in those severe COVID-19 …

… Until lately, data interpretation was limited to case reports and studies of non…
immunomodulatory agents and adjunctive therapies in the management of patients hospitalized with …

… However, it was difficult to interpret the efficacy of NAC in this case report as there was
concomitant treatment with higher than licensed dose of oseltamivir (150 mg twice-daily). As NAC …

… immunomodulatory agents, … immunomodulatory agents with good safety profiles may be
considered for use in combination with antiviral drugs for the treatment of severe or critical cases …

… immunomodulators as promising therapeutic agents in infectious diseases. A diverse array
of recombinant, synthetic and natural immunomodulatory … Immunomodulatory regimens offer …

… In most cases, the frequency and the severity of infection was reported to be reduced and
both the physician and the patient considered the treatment to be beneficial. In some patients …

… Severe and critical COVID-19 cases demand oxygen therapy and mechanical ventilator
support. Various drugs, including immunomodulatory and immunosuppressive agents (eg, …

… Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic
H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850–859. 8 Lee N, Choi KW, …